

Roche fact sheet

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014 the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs.


Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Roche's capabilities are augmented by technology collaborations and a constellation of worldwide alliances to help develop individual products and entire product portfolios.

Roche has one of the strongest drug development pipelines in the industry with 30 phase III projects and multiple projects currently in registration. The pipeline overall comprises over 60 new potential medicines and over 40 additional indications for existing medicines. Half of the projects in late-stage development utilise a companion diagnostic test and thus could help advance personalised healthcare.

Roche is recognised as a leader in Corporate Governance and Sustainability. Roche is listed on the FTSE4 Good Indices and is the 2014 Super Sector leader for healthcare in the Dow Jones Sustainability Indices (DJSI). Roche participates in various humanitarian and educational projects.

The Roche innovation network




Pharmaceuticals


The pharmaceuticals division is made up of Roche Pharma represented in over 150 countries, Genentech (the Group's US pharma business) and a majority shareholding of Chugai in Japan. Eight of Roche's 10 top-selling medicines are manufactured using biotechnology, and biopharmaceuticals account for more than 70% of pharmaceutical sales.

Global sales of top 10 medicines in 2014	CHF billion
MabThera/Rituxan ^{1,2}	6.9
Avastin ¹	6.4
Herceptin ¹	6.3
Lucentis ³	1.7
Tarceva ¹	1.3
Actemra/RoActemra ²	1.2
Pegasys ⁴	1.0
Xolair ²	1.0
Tamiflu ⁴	1.0
Perjeta ¹	0.9

Sales by therapeutic area 2014



Sales by region 2014




Diagnostics

Roche Diagnostics is the world leader in in vitro diagnostics; products used to test blood and other body fluids and tissue samples to obtain information for the diagnosis, treatment and monitoring of diseases. Its product portfolio ranges from blood glucose meters for people with diabetes and point-of-care testing devices for use in doctors' offices, to high-throughput analysers for hospitals and commercial diagnostic laboratories. The division also supplies state of the art instruments and reagents for life science research.

Sales by business area 2014



Sales by region 2014





Italics = growth rates as measured at constant exchange rates



1 Oncology
2 Immunology
3 Ophthalmology
4 Infectious diseases

Key financials

As reported in Swiss Francs (CHF)



Per security data as reported in Swiss Francs (CHF)



■ Pharmaceuticals ■ Diagnostics ■ Group

Additional information

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage.

The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Copyright © 3 March 2015 by Roche Investor Relations North America, South San Francisco.

Contact information

Investor Relations

F. Hoffmann-La Roche Ltd

CH-4070 Basel
Switzerland
Main switchboard: +41 61 688 1111
IR requests: +41 61 688 8880
Fax: +41 61 691 0014
investor.relations@roche.com
www.roche.com/investors

Karl Mahler
+41 61 687 8503
karl.mahler@roche.com

Peter Boyle
+41 61 688 3894
peter.boyle@roche.com

Tamer Farhan
+41 61 688 2552
tamer.farhan@roche.com

Sabine Borngraeber
+41 61 688 8027
sabine.borngraeber@roche.com

Bruno Eschli
+41 61 687 5284
bruno.eschli@roche.com

Birgit Masjost
+41 61 688 4814
birgit.masjost@roche.com

Investor Relations North America

Roche Holdings, Inc.

Genentech, Inc.

1 DNA Way
South San Francisco CA 94080
USA
Main number: +1 650 225 5566
Fax: +1 650 225 8326
rocheirna@gene.com

Stefan Foser
+1 650 467 2016
foser.stefan@gene.com

Nina Goworek
+1 650 467 8737
goworek.nina@gene.com

Stacy Galvin
+1 650 225 4150
galvin.stacy@gene.com

Ekaterine Kortkhonjia
+1 650 467 5873
kortkhonjia.ekaterine@gene.com

